GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology CommunicationsGlobeNewsWire • 08/10/23
Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeuticProactive Investors • 06/30/23
These strategists say investors need quality, so sell Tesla and AMD, and buy these stocks instead.Market Watch • 06/30/23
U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver diseaseMarket Watch • 06/30/23
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver diseaseGlobeNewsWire • 06/30/23
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver diseaseGlobeNewsWire • 06/30/23
GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023GlobeNewsWire • 06/07/23
Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)PRNewsWire • 05/31/23
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage AssetGlobeNewsWire • 05/31/23
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of HepatologyGlobeNewsWire • 05/23/23
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF ProgramGlobeNewsWire • 05/09/23
GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory DocumentsGlobeNewsWire • 04/19/23
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-FGlobeNewsWire • 04/18/23
GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/13/23
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver DiseasesGlobeNewsWire • 11/17/22
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®GlobeNewsWire • 10/25/22